What are the two drugs of dual immunotherapy with lpilimumab?

Ipilimumab (Ipilimumab) is usually combined with nivolumab (Nivolumab) to form a dual immunotherapy regimen. The two drugs are used together, often called combination immunotherapy, to boost the immune system's ability to attack cancer cells.

1.Ipilimumab (Ipilimumab): Ipilimumab is an immune checkpoint inhibitor that mainly works by inhibiting CT LA-4 (cytotoxicTlymphocyte antigen4) to enhance immune system activity. CTLA-4 is a protein that inhibits the activity of T lymphocytes, thereby reducing the immune system's attack on cancer cells. Ipilimumab works to relieve the suppression of the immune system by CTLA-4, making it easier for T lymphocytes to attack cancer cells. It is commonly used to treat malignant melanoma (melanoma) and some other cancer types.

2.Nivolumab (Nivolumab): Nivolumab is another immune checkpoint inhibitor that works by inhibiting PD-1 (programmed death 1) protein to enhance the activity of the immune system. PD-1 is a protein that plays a key role in regulating the immune system's response. Nivolumab works by blocking PD-1 and its ligand PD-L1 (programmed death ligand1) or PD-L2 binds, thereby enhancing the ability of T lymphocytes to attack cancer cells. The drug is used to treat a variety of cancer types, including melanoma, non-small cell lung cancer, colorectal cancer and more.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug costs about 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.